Triazole derivatives as modulators of mas-related g-protein receptor d

WO2023250181A8 Publication Date: 2025-03-20ESCIENT PHARMACEUTICALS INC
0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2023/026136
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-24
Filing Date
2023-06-23
Publication Date
2025-03-20

AI Technical Summary

Technical Problem

Current treatments for conditions associated with Mas-related G-protein coupled receptor D (MRGPRD) lack effective modulators, which are essential for addressing pain, itch, inflammatory, and other pathological conditions.

Method used

Development of triazole derivatives that act as modulators of MRGPRD, specifically compounds with defined structures that can be administered to treat MRGPRD-dependent conditions by interacting with the receptor to function as agonists, antagonists, or inverse agonists, thereby modulating its activity.

Benefits of technology

The triazole derivatives effectively treat MRGPRD-dependent conditions such as pain, itch, inflammatory disorders, and other diseases by specifically targeting and modulating the MRGPRD receptor, providing therapeutic benefits for various pathological conditions.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided is a compound having the structure of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate or isotope thereof, wherein A, B, R1, R2, R3, R4, R5, R6, R7, m, n, p, and y are as defined herein, for use in methods for modulating MRGPRD or for treating a MRGPRD dependent condition. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.
Need to check novelty before this filing date? Find Prior Art